Mahzad Akbarpour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahzad Akbarpour has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Pooya Farhangnia
Iran University of Medical Sciences
11 shared publications - Ali-Akbar Delbandi
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
8 shared publications Amir Reza Safdarian
Alborz University of Medical Sciences
6 shared publications- G. R. Scott Budinger
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA
5 shared publications - Ankit Bharat
Division of Thoracic Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
4 shared publications - Daniel Kreisel
Department of Surgery, Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO, USA
4 shared publications
Latest Publications
- 1 October 2025
- Published by Springer Nature
- p. 297-345
The Role of Intra-tumor Hypoxia in Cancer Cells Immune Escape Mechanism
- 1 October 2025
- Published by Springer Nature
- p. 297-345
The Role of Intra-tumor Hypoxia in Cancer Cells Immune Escape Mechanism
- 1 October 2025
- Published by Springer Nature
- p. 207-251
Bispecific Antibodies in Targeted Cancer Immunotherapy
- 1 October 2025
- Published by Springer Nature
- p. 207-251
Bispecific Antibodies in Targeted Cancer Immunotherapy
- 1 October 2025
- Published by Springer Nature
- p. 749-789
The Role of Inflammasome in Cancers and Potential Therapeutic Targets
- 1 October 2025
- Published by Springer Nature
- p. 749-789
The Role of Inflammasome in Cancers and Potential Therapeutic Targets
- 28 September 2024
- Published by Springer Nature
- p. 97-148
Cancer Immunotherapies Targeting Cancer Stem Cells: Concepts, Applications, and Advances
- 28 September 2024
- Published by Springer Nature
- p. 97-148
Cancer Immunotherapies Targeting Cancer Stem Cells: Concepts, Applications, and Advances
- Open Access
- 27 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1155778
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
Antibody-based cancer immunotherapy has become a powerful asset in the arsenal against malignancies. In this regard, bispecific antibodies (BsAbs) are a ground-breaking novel approach in the therapy of cancers. Recently, BsAbs have represented a significant advancement in improving clinical outcomes. BsAbs are designed to target two different antigens specifically. Over a hundred various BsAb forms currently exist, and more are constantly being manufactured. An antagonistic regulator of T cell activation is cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or CD152, a second counter-receptor for the B7 family of co-stimulatory molecules was introduced in 1996 by Professor James P. Allison and colleagues. Contrary to the explosive success of dual immune checkpoint blockade for treating cancers, a major hurdle still yet persist is that immune-related adverse events (irAEs) observed by combining immune checkpoint inhibitors (ICIs) or monoclonal antibodies such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). A promising strategy to overcome this hurdle is using BsAbs. This article will summarize BsAbs targeting CTLA-4, their applications in cancer immunotherapy, and relevant clinical trial advances. We will also discuss the pre-clinical rationale for using these BsAbs, and provide the current landscape of the field.
- 27 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1155778
Open AccessBispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
Antibody-based cancer immunotherapy has become a powerful asset in the arsenal against malignancies. In this regard, bispecific antibodies (BsAbs) are a ground-breaking novel approach in the therapy of cancers. Recently, BsAbs have represented a significant advancement in improving clinical outcomes. BsAbs are designed to target two different antigens specifically. Over a hundred various BsAb forms currently exist, and more are constantly being manufactured. An antagonistic regulator of T cell activation is cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or CD152, a second counter-receptor for the B7 family of co-stimulatory molecules was introduced in 1996 by Professor James P. Allison and colleagues. Contrary to the explosive success of dual immune checkpoint blockade for treating cancers, a major hurdle still yet persist is that immune-related adverse events (irAEs) observed by combining immune checkpoint inhibitors (ICIs) or monoclonal antibodies such as ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). A promising strategy to overcome this hurdle is using BsAbs. This article will summarize BsAbs targeting CTLA-4, their applications in cancer immunotherapy, and relevant clinical trial advances. We will also discuss the pre-clinical rationale for using these BsAbs, and provide the current landscape of the field.
- Open Access
- 11 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy
The signaling lymphocytic activation molecule (SLAM) family receptors were discovered in immune cells for the first time. The SLAM-family receptors are a significant player in cytotoxicity, humoral immune responses, autoimmune diseases, lymphocyte development, cell survival, and cell adhesion. There is growing evidence that SLAM-family receptors have been involved in cancer progression and heralded as a novel immune checkpoint on T cells. Previous studies have reported the role of SLAMs in tumor immunity in various cancers, including chronic lymphocytic leukemia, lymphoma, multiple myeloma, acute myeloid leukemia, hepatocellular carcinoma, head and neck squamous cell carcinoma, pancreas, lung, and melanoma. Evidence has deciphered that the SLAM-family receptors may be targeted for cancer immunotherapy. However, our understanding in this regard is not complete. This review will discuss the role of SLAM-family receptors in cancer immunotherapy. It will also provide an update on recent advances in SLAM-based targeted immunotherapies.
- 11 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
Open AccessSLAM-family receptors come of age as a potential molecular target in cancer immunotherapy
The signaling lymphocytic activation molecule (SLAM) family receptors were discovered in immune cells for the first time. The SLAM-family receptors are a significant player in cytotoxicity, humoral immune responses, autoimmune diseases, lymphocyte development, cell survival, and cell adhesion. There is growing evidence that SLAM-family receptors have been involved in cancer progression and heralded as a novel immune checkpoint on T cells. Previous studies have reported the role of SLAMs in tumor immunity in various cancers, including chronic lymphocytic leukemia, lymphoma, multiple myeloma, acute myeloid leukemia, hepatocellular carcinoma, head and neck squamous cell carcinoma, pancreas, lung, and melanoma. Evidence has deciphered that the SLAM-family receptors may be targeted for cancer immunotherapy. However, our understanding in this regard is not complete. This review will discuss the role of SLAM-family receptors in cancer immunotherapy. It will also provide an update on recent advances in SLAM-based targeted immunotherapies.
- 22 March 2023
- Published by Springer Nature
- p. 1-42
The Role of Inflammasome in Cancers and Potential Therapeutic Targets
- 22 March 2023
- Published by Springer Nature
- p. 1-42
The Role of Inflammasome in Cancers and Potential Therapeutic Targets
- 26 January 2023
- Published by Springer Nature
- p. 1-46
Bispecific Antibodies in Targeted Cancer Immunotherapy
- 26 January 2023
- Published by Springer Nature
- p. 1-46
Bispecific Antibodies in Targeted Cancer Immunotherapy
- Open Access
- 10 June 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 859633
Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside
Glioblastoma (grade IV glioma) is the most aggressive histopathological subtype of glial tumors with inordinate microvascular proliferation as one of its key pathological features. Extensive angiogenesis in the tumor microenvironment supplies oxygen and nutrients to tumoral cells; retains their survival under hypoxic conditions; and induces an immunosuppressive microenvironment. Anti-angiogenesis therapy for high-grade gliomas has long been studied as an adjuvant immunotherapy strategy to overcome tumor growth. In the current review, we discussed the underlying molecular mechanisms contributing to glioblastoma aberrant angiogenesis. Further, we discussed clinical applications of monoclonal antibodies, tyrosine kinase inhibitors, and aptamers as three major subgroups of anti-angiogenic immunotherapeutics and their limitations. Moreover, we reviewed clinical and preclinical applications of small interfering RNAs (siRNAs) as the next-generation anti-angiogenic therapeutics and summarized their potential advantages and limitations. siRNAs may serve as next-generation anti-angiogenic therapeutics for glioma. Additionally, application of nanoparticles as a delivery vehicle could increase their selectivity and lower their off-target effects.
- 10 June 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 859633
Open AccessNext-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside
Glioblastoma (grade IV glioma) is the most aggressive histopathological subtype of glial tumors with inordinate microvascular proliferation as one of its key pathological features. Extensive angiogenesis in the tumor microenvironment supplies oxygen and nutrients to tumoral cells; retains their survival under hypoxic conditions; and induces an immunosuppressive microenvironment. Anti-angiogenesis therapy for high-grade gliomas has long been studied as an adjuvant immunotherapy strategy to overcome tumor growth. In the current review, we discussed the underlying molecular mechanisms contributing to glioblastoma aberrant angiogenesis. Further, we discussed clinical applications of monoclonal antibodies, tyrosine kinase inhibitors, and aptamers as three major subgroups of anti-angiogenic immunotherapeutics and their limitations. Moreover, we reviewed clinical and preclinical applications of small interfering RNAs (siRNAs) as the next-generation anti-angiogenic therapeutics and summarized their potential advantages and limitations. siRNAs may serve as next-generation anti-angiogenic therapeutics for glioma. Additionally, application of nanoparticles as a delivery vehicle could increase their selectivity and lower their off-target effects.
- 21 April 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 109, 108786
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
- 21 April 2022
- Published by Elsevier in International Immunopharmacology
- Vol. 109, 108786
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials